KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Issued
Ratios

Gilead Sciences (GILD) EBIAT (2016 - 2025)

Gilead Sciences' EBIAT history spans 17 years, with the latest figure at $2.2 billion for Q4 2025.

  • For Q4 2025, EBIAT rose 22.43% year-over-year to $2.2 billion; the TTM value through Dec 2025 reached $8.5 billion, up 1672.92%, while the annual FY2025 figure was $8.5 billion, 1672.92% up from the prior year.
  • EBIAT reached $2.2 billion in Q4 2025 per GILD's latest filing, down from $3.1 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $3.1 billion in Q3 2025 to a low of -$4.2 billion in Q1 2024.
  • Average EBIAT over 5 years is $1.3 billion, with a median of $1.6 billion recorded in 2021.
  • Peak YoY movement for EBIAT: surged 8316.67% in 2023, then crashed 512.87% in 2024.
  • A 5-year view of EBIAT shows it stood at $400.0 million in 2021, then surged by 303.5% to $1.6 billion in 2022, then fell by 11.46% to $1.4 billion in 2023, then increased by 24.77% to $1.8 billion in 2024, then grew by 22.43% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's EBIAT are $2.2 billion (Q4 2025), $3.1 billion (Q3 2025), and $2.0 billion (Q2 2025).